Patents by Inventor Erik Mogalian

Erik Mogalian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination formulation of two antiviral compounds
    Patent number: 11707479
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: July 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • ANTIBODY COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20220380441
    Abstract: The present disclosure relates to pharmaceutical compositions that comprise an antibody that neutralizes infection of hepatitis B virus (HBV). In addition, the present disclosure relates to the use of the pharmaceutical compositions in the treatment of HBV infection.
    Type: Application
    Filed: August 28, 2020
    Publication date: December 1, 2022
    Inventors: Phillip S. PANG, Erik MOGALIAN, Lynn E. CONNOLLY, Jonathan GALL
  • COMPOSITIONS AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION
    Publication number: 20220306728
    Abstract: The present disclosure provides antibodies, antibody compositions, and methods for use in prophylaxis and treatment of influenza A infection. In certain embodiments, a single administration of a presently disclosed antibody or antibody composition is useful to protect against and/or treat an influenza A infection for a full flu season.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 29, 2022
    Inventors: Phillip S. PANG, Lynn E. CONNOLLY, Erik MOGALIAN
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20220072021
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 10, 2022
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • Combination formulation of two antiviral compounds
    Patent number: 11116783
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 14, 2021
    Assignee: Gilead Pharmasset LLC
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20210000854
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20200188419
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20190240246
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: September 6, 2018
    Publication date: August 8, 2019
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20190111068
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: July 20, 2018
    Publication date: April 18, 2019
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • Combination formulation of two antiviral compounds
    Patent number: 10086011
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 2, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • Combination formulation of two antiviral compounds
    Patent number: 10039779
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: August 7, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20180021362
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: August 7, 2017
    Publication date: January 25, 2018
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • SOLID FORMS OF AN ANTIVIRAL COMPOUND
    Publication number: 20170327488
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 16, 2017
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang
  • Combination formulation of two antiviral compounds
    Patent number: 9757406
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 12, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20170202865
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: December 29, 2016
    Publication date: July 20, 2017
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • Solid forms of an antiviral compound
    Patent number: 9682987
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: June 20, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20170095499
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20160120892
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: September 28, 2015
    Publication date: May 5, 2016
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • SOLID FORMS OF AN ANTIVIRAL COMPOUND
    Publication number: 20150344488
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5 -(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro [2 .4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Application
    Filed: August 13, 2015
    Publication date: December 3, 2015
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang
  • Solid forms of an antiviral compound
    Patent number: 9139570
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: September 22, 2015
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang